SCHEMBL2199740

SCHEMBL2199740

CC(C)(C)N(CCCCl)C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15263747 0.94 MEN1 (0.32) MEN1HTTKMT2AL3MBTL1
SCHEMBL3898144 0.86 HTT (0.34) MEN1HTTKMT2AL3MBTL1
SCHEMBL19025042 0.80 FOLH1 (0.36) MEN1HTTKMT2AL3MBTL1
SCHEMBL15569600 0.80 MEN1 (0.33) MEN1HTTKMT2AL3MBTL1
SCHEMBL10830752 0.80 CA12 (0.40) MEN1KMT2A
SCHEMBL790160 0.80 MEN1 (0.33) MEN1HTTKMT2AL3MBTL1
SCHEMBL167777 0.78 MEN1 (0.33) MEN1HTTKMT2AL3MBTL1
SCHEMBL3399507 0.78 MEN1 (0.33) MEN1HTTKMT2AL3MBTL1
SCHEMBL838329 0.78 KMT2A (0.36) MEN1HTTKMT2AL3MBTL1
SCHEMBL29029803 0.78 AKR1B1 (0.39) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210107871-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2021-04-15 US disclosed
EP-3611161-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY National University Corporation Hokkaido University (JP) 2020-02-19 EP disclosed
US-9957291-B2 Protected fluorescent reagent compounds PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2018-05-01 US disclosed
US-20150050659-A1 PROTECTED FLUORESCENT REAGENT COMPOUNDS PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2015-02-19 US disclosed
US-7977334-B2 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150050659-A1 PROTECTED FLUORESCENT REAGENT COMPOUNDS ERCC4, ERCC2, ERCC1 MEN1 2015/4885HTT 595/4885KMT2A 1933/4885
US-20210107871-A1 BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY FLNA, FLNB, BRI3BP MEN1 4456/4885HTT 4145/4885KMT2A 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.